Table 1.
Baseline characteristics of patients with HCC undergoing TACE included in this study.
| Variable | All Patients (n = 280) | Patients Classified as BCLC B (n = 154) |
|---|---|---|
| Age, years | 69.5 (62.5–75.4) | 70.2 (63.3–75.6) |
| Sex, n (%) | ||
| Female | 46 (16.4) | 23 (14.9) |
| Male | 234 (83.6) | 131 (85.1) |
| Etiology, n (%) | ||
| Alcohol | 131 (46.8) | 70 (45.5) |
| Hepatitis C | 46 (16.4) | 25 (16.2) |
| Hepatitis B | 26 (9.3) | 17 (11.0) |
| NASH | 27 (9.6) | 15 (9.7) |
| Hemochromatosis | 5 (1.8) | 3 (2.0) |
| AIH/PBC/PSC | 5 (1.8) | 3 (2.0) |
| Unknown/Other | 29 (10.4) | 13 (8.4) |
| None | 11 (3.9) | 8 (5.2) |
| Child–Pugh stage, n (%) | ||
| A | 104 (37.2) | 60 (39.0) |
| B | 116 (41.4) | 74 (48.0) |
| C | 25 (8.9) | 0 |
| No cirrhosis | 35 (12.5) | 20 (13.0) |
| BCLC stage, n (%) | ||
| 0 | 0 | 0 |
| A | 45 (16.1) | 0 |
| B | 154 (55.0) | 154 (100) |
| C | 58 (20.7) | 0 |
| D | 23 (8.2) | 0 |
| Max. tumor size, cm | 4.2 (2.9–6.4) | 4.3 (3.2–6.1) |
| Tumor number, n (%) | ||
| Unifocal | 55 (19.6) | 0 |
| Multifocal | 203 (72.5) | 146 (94.8) |
| Diffuse growth pattern | 22 (7.9) | 8 (5.2) |
| Albumin level, g/L | 31 (27–35) | 31 (28–35) |
| Lymphocyte count, per mm3 | 1214 (83–1558) | 1263 (841–1660) |
| Bilirubin level, mg/dL | 1.3 (0.8–2.2) | 1.3 (0.9–2.0) |
| Platelet count, per nL | 128 (87–193) | 119 (84–194) |
| AST level, U/L | 64.5 (47.0–95.5) | 63.0 (47.0–88.5) |
| ALT level, U/L | 41.5 (28.0–61.0) | 42.0 (28.0–62.0) |
| AP level, U/L | 156.0 (114.0–212.3) | 146.5 (104.0–201.8) |
| CRP level, mg/L | 9.0 (3.6–18.0) | 8.0 (3.6–15.8) |
| INR | 1.2 (1.1–1.3) | 1.1 (1.0–1.3) |
| AFP level, ng/mL | 45.0 (8.1–777.0) | 48.0 (7.6–593.5) |
Values are given as n (%) or median (interquartile range) unless otherwise noted. NASH, nonalcoholic steatohepatitis. AIH, autoimmune hepatitis. PBC, primary biliary cholangitis. PSC, primary sclerosing cholangitis. BCLC, Barcelona Clinic Liver Cancer. AST, aspartate aminotransferase. ALT, alanine aminotransferase. AFP, alpha fetoprotein.